Loading Events

Shattuck Labs Investor Call and Webcast on Additional Data Presented at the EHA 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

DATE: June 14, 2024

About The Event

Join Shattuck Labs, Inc. for an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the European Hematology Association (EHA) 2024 Congress. The event will feature key opinion leader, Dr. Naval G. Daver, MD from The University of Texas MD Anderson Cancer Center. 

SL-172154 (SIRPα-Fc-CD40L) is an investigational ARC® fusion protein designed to simultaneously inhibit the CD47/SIRPα checkpoint interaction and activate the CD40 costimulatory receptor to bolster an anti-tumor immune response in patients with advanced cancer.

A live question and answer will follow the formal presentation.